Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases

• Published in: Current medical research and opinion Vol. 24; no. 4; pp. 1011 - 1015
• Main Authors: Izzo, Francesco, Di Giacomo, Raimondo, Falco, Paolo, Piccirillo, Mauro, Iodice, Rossana, Pio Orlando, Antonio, Aprea, Pasquale, Cremona, Francesco, Di Marzo, Massimiliano, Nicola Idà, Domenico, Mastro, Angelo A., Curley, Steven A.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.04.2008
• Subjects: Blood Loss, Surgical - prevention & control; Female; Gels; Hemostasis - drug effects; Hepatectomy - methods; Humans; Italy; Liver Neoplasms - surgery; Male; Middle Aged; Postoperative Hemorrhage - prevention & control; Prospective Studies; Thrombin - administration & dosage; Time Factors; Italy
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1185/030079908X280392

ABSTRACT Background: The haemostatic matrix (FloSeal*) is a topical agent that provides effective haemostasis in a range of surgical applications. We evaluated this sealant for intra-operative haemostatic effectiveness in an observational series of patients undergoing surgery for the resection of primary and metastatic liver tumours. Methods: A haemostatic matrix was applied directly to areas of bleeding. The severity of bleeding before and after application was graded on a 5-point scale (0 = no bleeding, 1 = oozing, 2 = moderate blood flow, 3 = heavy blood flow, 4 = spurting blood). The time to complete haemostasis was also recorded. Results: 105 women (age 61 ± 9 years) and 132 men (age 61 ± 12 years) were included in this study. One hundred and seventeen patients (49.36%) had pre-operative coagulopathy resulting from co-existent cirrhosis (67 Child-Pugh Class A; 50 Child-Pugh Class B). Prior to administration of a haemostatic matrix, 93 bleeding sites (24.8%) had a bleeding severity score of 2, 269 bleeding sites (71.7%) had a score of 3 and 13 bleeding sites (3.5%) had a score of 4. Following administration of the haemostatic matrix, bleeding stopped completely (score of 0) at 367 (97.9%) of the 375 sites and was reduced to a score of 1 at the remaining 8 sites (2.1%), of which only 2 were in patients with coagulopathy. The mean time to achieve haemostasis in the overall population was 2.9 ± 1 min; this was significantly increased in patients with coagulopathy versus non-coagulopathic patients (4 ± 1 vs. 2 ± 1 min, p < 0.001). Conclusions: In this prospective, uncontrolled study of 237 consecutive patients undergoing major hepatic surgery to remove primary or metastatic tumours, application of a haemostatic matrix provided rapid and effective intra-operative control of mild to severe bleeding from the liver edge, even in patients with prolonged bleeding times resulting from cirrhosis. This preliminary evidence warrants a randomised, controlled clinical trial with a larger sample size.